Key result
This randomized controlled study protocol outlines a cross-over trial to evaluate the effect of liraglutide added to metformin on left ventricular ejection fraction in 40 patients with CAD and T2DM.
Why the study?
Does liraglutide added to metformin improve left ventricular ejection fraction during stress echocardiography and β-cell function in patients with CAD and newly diagnosed T2DM?
Population
40 patients with coronary artery disease (CAD) and newly diagnosed type-2 diabetes mellitus (T2DM)
Comparison
Liraglutide added to metformin backbone therapy vs Placebo added to metformin backbone therapy
Design
Other, randomised, double blind, placebo-controlled
Follow-up
12 plus 12 weeks cross-over with a 2-week washout period
Authors
Loading...
This study protocol describes a randomized cross-over trial to assess the effects of liraglutide on cardiac and beta-cell function in patients with CAD and newly diagnosed T2DM.
RCT (n=40)
double blind
cross-over
Does liraglutide added to metformin improve left ventricular ejection fraction during stress echocardiography and β-cell function in patients with CAD and newly diagnosed T2DM?
This study protocol describes a randomized cross-over trial to assess the effects of liraglutide on cardiac and beta-cell function in patients with CAD and newly diagnosed T2DM.
Anholm et al. (2014) conducted an RCT in coronary artery disease and newly diagnosed type-2 diabetes (n=40). liraglutide + metformin vs. placebo + metformin was evaluated on changes in left ventricular ejection fraction during stress echocardiography and β-cell function. This randomized controlled study protocol outlines a cross-over trial to evaluate the effect of liraglutide added to metformin on left ventricular ejection fraction in 40 patients with CAD and T2DM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: